On January 20, 2026, Imexpharm Corporation announced its 2025 financial results, reporting net revenue of VND 2,441 billion, up 10.7% year-on-year, and gross revenue of...
In September 2025, Imexpharm’s profit before tax surged by 101%, while EBITDA increased by 48%. For the first nine months of 2025, the company’s gross and net...
In recent years, the “One Commune One Product” (OCOP) programme has become a key driver of rural economic development in the former Hoa Binh Province, now part of Phu...
The revised Pharmaceutical Law and strategic investments are paving the way for Imexpharm’s high growth in 2025, with a bold revenue target of approximately 3...
While a number of foreign companies have moved part of their production or orders to other countries, many still see Vietnam as a good location for investment in the...
VN
EN